DIPEPTIDYL PEPTIDASE-4 INHIBITORS IN COMBINATION WITH METFORMIN: EXPERIENCE OF USE OF GALVUS MET IN REAL-LIFE CLINICAL PRACTICE IN MOSCOW
- Authors: Antsiferov MB1, Antsiferov MB1
-
Affiliations:
- Issue: No 7 (2012)
- Pages: 70-74
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279502
- ID: 279502
Cite item
Full Text
Abstract
The article presents the analysis of results of one year's follow-up of 1922 patients with type 2 diabetes mellitus within the framework of the observational program "Efficacy of Galvus Met in real-life clinical practice of endocrinologist." In general, the 12-month treatment with Galvus Met (vildagliptin + metformin) provided clinically significant improvement in glycemic control with good tolerability. More than 96% of patients expressed satisfaction with the therapy and desire to continue therapy in the future. In addition, treatment had a positive effect on body weight and blood pressure.
References
- Schweizer A, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med 2007;24:955-61.
- Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15(6):540-59.
- Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2 типа. М., 2010. 92 с.
- Дедов И.И., Шестакова М.В., Аметов А.С. и др. Проект "Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии сахарного диабета 2 типа" //Сахарный диабет 2011. Т. 50. № 1. С. 95-105.
- Bosi E, et al. Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients with Type 2 Diabetes Inadequately Controlled with Metformin. Diabetes Care 2007;30:890-95.
- Ahrén B, Pacini G, et al. Improved meal-related b-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-40.
- Bosi E, et al. Improved Blood Pressure (BP) Lowering in Hypertensive Patients (pts) with Type 2 Diabetes (T2DM) with Vildagliptin Combined with Metformin Compared with Metformin Alone. Presented at ADA, 22-26 June 2007.
- Fonseca V, Schweizer A, Baron MA, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-55.
- Ferrannini E, et al. 52-week efficacy and safety of vildagliptin versus glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11(2):157-66.
- Garber A, et al. Effects of Vildagliptin on Glucose Control in Patients with Type 2 Diabetes Inadequately Controlled with a Sulphonylurea. Diabetes Obes Metab 2008;10:1326-463.
- Bosi E, et al. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naïve patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009;11:506-15.
- Bourdel-Marchasson I, SchweizerA, Dejager S. Incretin Therapies in the Management of Elderly Patients with Type 2 Diabetes Mellitus. Hospital Practice 2011;39(1):1-15.
- Анциферов М.Б. Клинические аспекты применения и-ДПП-4 в комбинации с метформином: преимущества для разных групп пациентов // Фарматека 2011. № 3. С. 50-5.
- Анциферов М.Б., Зилов А.В. Перспективы применения и-ДПП-4 при СД 2 типа: инициация и продолжение терапии // Фарматека 2010. № 16. С. 12-17.
- Дедов И.И., Шестакова М.В. Алгоритмы специализированной медицинской помощи пациентам с сахарным диабетом, 5-й выпуск. М., 2011.
- Перечень жизненно необходимых и важнейших лекарственных препаратов. Распоряжение Правительства Российской Федерации от 11 ноября 2010 г. № 1938-р.
Supplementary files
